combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and its use in the treatment of hepatitis c, hepatic fibrosis and impaired liver function
ROCHE PALO ALTO LLC;F. HOFFMANN-LA ROCHE LTD.;PHARMASSET, INC.
发明人:
ABEL DE LA ROSA,ELLEN S. YETZER,MICHAEL D. ROGERS,PATRICK F. SMITH,STEVEN B. PORTER,WILLIAM T. SYMONDS,WILLIAMSON ZIEGLER BRADFORD
申请号：
BRPI1009338
公开号：
BRPI1009338A2
申请日:
2010.02.26
申请国别(地区):
BR
年份:
2016
代理人:
摘要：
Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.
